Journal of Affective Disorders
January 15, 2016
Megha M Vasavada, Amber M Leaver, Randall Espinoza et al.
58 citations
Ketamine elicits an acute antidepressant effect in patients with major depressive disorder (MDD). Here, we used diffusion imaging to explore whether regional differences in white matter microstructure prior to treatment may predict clinical response 24h following ketamine infusion in 10 MDD patients. FSL's Tract-Based Spatial Statistics (TBSS) established voxel-level differences in fractional...
BMC Medical Ethics
January 14, 2016
Melvyn W B Zhang, Keith M. Harris, Roger Ho
69 citations
BACKGROUND: Depressive disorders are a common form of psychiatric illness and cause significant disability. Regulation authorities, the medical profession and the public require high safety standards for antidepressants to protect vulnerable psychiatric patients. Ketamine is a dissociative anaesthetic and a derivative of a hallucinogen (phencyclidine). Its abuse is a major worldwide public...
The World Journal of Biological Psychiatry
January 11, 2016
Matthew N. Cooper, Joshua D. Rosenblat, Danielle S. Cha et al.
40 citations
Objectives Replicated evidence has demonstrated that ketamine exerts rapid-acting and potent antidepressant effects. Notwithstanding, its promise to mitigate depressive symptoms and suicidality in antidepressant-resistant populations, several limitations and safety concerns accompany ketamine including, but not limited to, the potential for abuse and psychotomimetic/dissociative experiences....
Acta neurobiologiae experimentalis
2016
Filiz Civil Arslan, Ahmet Tiryaki, Mehmet Yıldırım et al.
12 citations
Bipolar disorder is a chronic disease characterized by recurring episodes of mania and depression that can lead to disability. This study investigates the protective effects of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a drug with well-known antioxidant properties, in a model of mania induced by ketamine in rats. Locomotor activity was assessed in the open-field test. Superoxide...
2016
Mingfa Huang, Ke Zhang, Xiang Cai
The mechanisms underlying the rapid-acting antidepressant effects of ketamine have not been fully identified. In current study, we observed that a single subanesthesia dose of ketamine strongly decreased the immobility time of Sprague–Dawley rats in forced swim test. Ketamine injection significantly increased GluR1 expression and GluR1 Ser845 phosphorylation in prefrontal cortex....
International Journal on Disability and Human Development
2016
Theodore Kastner, Kevin Walsh, Lisa Shulman et al.
Abstract: Autism or autism spectrum disorder (ASD) is a behavioral syndrome characterized by (a) persistent deficits in social communication and social interaction across multiple contexts and (b) restricted, repetitive patterns of behavior, interests or activities. However, the etiology of autism in most cases remains unknown. Ketamine, an N-Methyl-D-aspartate (NMDA) blocker, has been...
2016
Michael A. Cerullo, A. Stryker
In severe depression thoughts of suicide can develop over weeks or months. Traditional pharmacologic or psychotherapeutic treatments take several weeks before they begin to improve symptoms. This gradual improvement is consistent with our everyday experience of the self. However, a new treatment, ketamine, can alter depressive symptoms within hours or even minutes. Ketamine can stop suicidal...
The Brown University Psychopharmacology Update
2016
A review and meta‐analysis of the effects of N‐methyl‐D‐aspartate (NMDA) receptor antagonists in treating major depression has confirmed that ketamine is the only such drug to date that has demonstrated antidepressant efficacy across multiple trials. Authors of the review stated, however, that the findings regarding ketamine should be viewed with caution because the beneficial effects are not...
PeerJ
2016
Jing J Wong, Owen O'Daly, Mitul A. Mehta et al.
Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of treatment-resistant depression. In this study, we investigate whether an acute administration of ketamine leads to reductions in the functional connectivity of subgenual anterior cingulate cortex (sgACC) with other brain regions. Methods. Thirteen right-handed healthy male subjects underwent a 15...
Indian Journal of Psychological Medicine
2016
Mahesh Ramanna Gowda, Preethi Srinivasa, Prabha S Kumbar et al.
Ketamine, a primarily FDA-approved anaesthetic agent is also used as recreational drug. Based on preclinical findings and later the clinical observations it is noted to have rapid antidepressant effect due to its mechanisms related to NMDA antagonism. In spite of established evidence of ketamine being effective in depression with significant role in treatment resistant cases as well, there was...